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ARTICLE
A ribose-functionalized NAD+ with unexpected
high activity and selectivity for protein poly-ADP-
ribosylation
Xiao-Nan Zhang1,7, Qinqin Cheng1,7, Jingwen Chen1, Albert T. Lam1, Yanran Lu1, Zhefu Dai1, Hua Pei2,
Nikolai M. Evdokimov3, Stan G. Louie2 & Yong Zhang 1,4,5,6
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important
roles in physiology and pathophysiology. It has been challenging to study this key type of
enzymatic post-translational modification in particular for protein poly-ADP-ribosylation
(PARylation). Here we explore chemical and chemoenzymatic synthesis of NAD+ analogues
with ribose functionalized by terminal alkyne and azido groups. Our results demonstrate that
azido substitution at 3′-OH of nicotinamide riboside enables enzymatic synthesis of an NAD+
analogue with high efficiency and yields. Notably, the generated 3′-azido NAD+ exhibits
unexpected high activity and specificity for protein PARylation catalyzed by human poly-
ADP-ribose polymerase 1 (PARP1) and PARP2. And its derived poly-ADP-ribose polymers
show increased resistance to human poly(ADP-ribose) glycohydrolase-mediated degrada-
tion. These unique properties lead to enhanced labeling of protein PARylation by 3′-azido
NAD+ in the cellular contexts and facilitate direct visualization and labeling of mitochondrial
protein PARylation. The 3′-azido NAD+ provides an important tool for studying cellular
PARylation.
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Numerous biological processes are orchestrated by proteinpost-translational modifications (PTMs)1. Among keyPTMs is protein ADP-ribosylation catalyzed by a super-
family of enzymes named ADP-ribosyltransferases (ARTs) with
nicotinamide adenine dinucleotide (NAD+) as a cosubstrate. The
human genome is found to encode 20 ART enzymes including
intracellular poly-ADP-ribose polymerases (PARPs) and sirtuins
(SIRTs) and ecto-ART1-52, which possess poly- or mono-ADP-
ribosylation activity. Protein ADP-ribosylation plays vital roles in
regulating genome stability, protein homeostasis, cell proliferation,
differentiation and apoptosis2–5. In the human ART superfamily,
17 members (85%) are strongly implicated in various human
diseases5–19. The activation or enhancement of those ART enzy-
matic activities positively correlate with pathogenesis and pro-
gression of those diseases. Given their importance and emerging
roles in a wide range of prevalent human diseases, ART enzymes
have attracted considerable interest for early diagnosis and treat-
ment of disease. To study NAD+-dependent ADP-ribosylation, a
number of NAD+ analogues were chemically synthesized, which
are featured with modified adenines by alkyne, biotin, and fluor-
escent groups20–27 to label and profile substrate proteins and/or
visualize cellular ADP-ribosylation. The established NAD+ ana-
logues with substituted adenines raise the question of whether
functional groups can be attached to other positions for generating
NAD+ molecules with enhanced and/or new functions.
Herein, we explore the generation of a series of ribose-
functionalized NAD+ analogues using chemical and che-
moenzymatic approaches (Fig. 1). It is found that recombinant
human nicotinamide riboside kinase 1 (NRK1) and nicotinamide
mononucleotide adenylyltransferase 1 (NMNAT1) can efficiently
catalyze formation of 3′-azido NAD+ from its nicotinamide
riboside (NR) analogue precursor in the presence of adenosine
triphosphate (ATP). Enzyme- and cell-based assays indicate that
3′-azido NAD+ displays excellent substrate activity for protein
poly-ADP-ribosylation (PARylation), comparable to that of
native NAD+. Importantly, in comparison to established
adenine-modified NAD+ analogues with strong activities for
ADP-ribosylation, the 3′-azido NAD+ displays unexpected
higher activity and selectivity for protein PARylation catalyzed by
human PARP1 and PARP2. Moreover, the 3′-azido NAD+-based
poly-ADP-ribose (PAR) polymers reveal improved resistance to
degradation by human poly(ADP-ribose) glycohydrolase
(PARG). These unique properties for the 3′-azido NAD+ col-
lectively result in more significant labeling of protein PARylation
in the cell lysates relative to NAD+ and adenine-substituted
NAD+ analogues and enable direct visualization and labeling of
mitochondrial protein PARylation. This ribose-functionalized
NAD+ with marked activity and specificity for protein PARyla-
tion not only offers an important tool for studying post-
translational ADP-ribosylation but also may pave the ways
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Fig. 1 Biosynthesis of NAD+ and ribose-functionalized NAD+ analogues. a NRK- and NMNAT-catalyzed formation of NAD+. b Enzymatic synthesis of
NAD+ analogues with functionalized riboses for protein PARylation. c Chemical structures of NAD+ analogue 1–6. PPi: pyrophosphate; Nam: nicotinamide;
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toward the creation of bi- and multi-functional NAD+ molecules
for investigating PARylation-dependent signaling and processes.
Results
Chemical and enzymatic synthesis of NAD+ analogues.
Inspired by NRK- and NMNAT-mediated biosynthesis of NAD+
from NR (Fig. 1a), we envisioned that ribose-functionalized NR
may allow facile chemoenzymatic synthesis of NAD+ analogues
(Fig. 1b). Human NRK1 and NMNAT1 display adequate catalytic
activities for NR+ATP and nicotinamide mononucleotide
(NMN)+ATP, respectively, and promiscuity toward other sub-
strate analogues28–30. X-ray structures of human NRK1 and
NMNAT1 support that ribose-functionalized NR and NMN are
likely recognized for catalysis31,32 (Supplementary Fig. 1).
Moreover, previous studies showed that leaving group activation
is an important catalytic force for reactions catalyzed by multiple
N-ribosyltransferases33–38. Combined with structural analysis of
PARP active sites, these results suggest that modifications of NR
ribosyl 2′-OH and 3′-OH with terminal alkyne and azido groups
can possibly result in bioorthogonal NAD+ with considerable
substrate activities and a facile approach for the production of
NAD+-based chemical tools. Importantly, such ribose-
functionalized NAD+ may allow incorporation of additional
functional groups at distinct positions without signicant loss of
substrate activity for the development of NAD+ molecules with
dual or multiple functions.
To test this notion, propargyl, pentynyl, and azido were chosen
for modifications of NR 2′-OH and 3′-OH to generate 1–6
(Fig. 1c and Supplementary Figs. 2–8). The stereochemistries of
the generated intermediates O-benzoyl protected NR1-6 were
determined as β-isomers on the basis of 1H–1H COSY
experiments to confirm proton assignments and subsequent
NOESY experiments (Supplementary Figs. 9–21). The resulting
NR1-6 were then subjected to 5′-phosphorylation and pyropho-
sphate coupling with adenosine monophosphate (AMP) for
chemical synthesis of 1–6 (Supplementary Figs. 2–8).
To explore enzymatic synthesis of 1–6 from their correspond-
ing NR and NMN analogues, human NRK1 and NMNAT1 were
expressed and purified from Escherichia coli (Supplementary
Table 1 and Supplementary Fig. 22). In vitro biosynthesis of
NAD+ from NR was first carried out using purified NRK1 and
NMNAT1. In the presence of NRK1 and NMNAT1 and ATP, a
substantial amount of NAD+ was formed from NR after 40 h
incubation (Fig. 2a, b). Then, enzymatic syntheses of 1–6 were
attempted under the same conditions. It was found that a
significant amount of 5 and 6 could be generated by incubating
NR5 and NR6 with ATP and NRK1 and NMNAT1 at room
temperature for 24 or 40 h (Supplementary Fig. 23 and Fig. 2c, d),
while incubation of other NR analogues NR1-4 with ATP and the
purified enzymes gave no formation of NAD+ analogues 1–4
(Supplementary Fig. 23). Compared with an 83% isolated yield
for biosynthesis of NAD+ from NR (Supplementary Fig. 24 and
Fig. 2a, b), the two-step enzymatic approach gave rise to a 68%
isolated yield for the production of 6 starting from NR6
(Supplementary Fig. 25 and Fig. 2c, d). Using this enzymatic
method, 12.2 mg of 6 was facilely produced and puried for the
later experiments. In contrast, chemical synthesis of 6 from NR6
revealed a combined yield of 32% (Supplementary Fig. 8) and the
pyrophosphate coupling step needs four days plus tedious and
challenging HPLC purification. These results demonstrate a facile
and efficient chemoenzymatic approach for generating 3′-azido
NAD+.
Additionally, NR1-6 and NMN1-6 were examined separately
with purified NRK1 and NMNAT1 to determine their substrate
activities for enzymatic conversions. Compared with NRK1 that
could only catalyze conversion of NR5 and NR6, NMNAT1
displayed higher tolerance to these ribosyl modifications and was
shown to catalyzes formation of 1, 2, 5 and 6 from respective
NMN precursors (Supplementary Figs. 26–28). HPLC analysis
revealed that NMN6 could be rapidly converted to 6 within 4 h in
a 74% yield at the milligram level (Supplementary Fig. 29 and
Fig. 2e). These results indicate that the azido substitution at NR
3′-OH position allows efficient enzymatic synthesis of 6, in
particular from its NMN analogue precursor.
Substrate activities of NAD+ analogues for human PARP1. To
evaluate substrate activities of 1–6 for protein PARylation, full-
length human PARP1 was expressed and purified from E. coli.
Human PARP1 is a well-characterized enzyme for protein
PARylation. In addition to catalyzing PARylation on various
types of cellular proteins, PARP1 also undergoes robust auto-
PARylation in the presence of NAD+ and DNA fragments. The
substrate activities of 1–6 were first evaluated by performing
PARP1-catalyzed automodification with highly pure 1–6 (Sup-
plementary Fig. 30 and Supplementary Table 2). It was shown
that both NAD+ and 6 resulted in strong auto-PARylation of
PARP1, which could be potently suppressed by veliparib, an
inhibitor of PARP1-PARP4 (Fig. 3a). This also indicates that the
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Fig. 2 HPLC analysis of enzymatic formation of NAD+ and 6. a Assigned
peaks for standard compounds of NR, NMN, NAD+ and ATP. b One
millimolar NR was incubated with 5mM ATP, 5 µM NRK1, and 5 µM
NMNAT1 at RT for 40 h, followed by HPLC analysis. c Assigned peaks for
standard compounds of NR6, NMN6, 6 and ATP. d One millimolar NR6 was
incubated with 5 mM ATP, 5 µM NRK1, and 5 µM NMNAT1 at RT for 40 h,
followed by HPLC analysis. e One millimolar NMN6 was incubated with
5 mM ATP, 5 µMNRK1, and 5 µMNMNAT1 at RT for 4 h, followed by HPLC
analysis. UV absorbance was measured at 260 nm. AU: absorbance unit
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anti-PAR antibody can recognize the 3′-azido NAD+-derived
PAR polymers. Since 6 contains an azido group, which is
bioorthogonal to biotin-conjugated alkynes through click chem-
istry, auto-modified PARP1 by NAD+ and 6 were then clicked
with biotin and detected by a streptavidin-HRP conjugate. Con-
sistent with the immunoblot results using the anti-PAR antibody,
PARP1 modified by 6 revealed strong PARylation signals that
were sensitive to veliparib treatment (Fig. 3b). Due to the lack of
azido group for NAD+, no PARylation signals were observed for
NAD+-modified PARP1 on this biotinylation-based immunoblot.
In comparison, 5 with an azido group attached to NR 2′-OH
displayed no PARylation signals (Supplementary Figs. 31 and 32).
Similarly, 1 and 3 containing 2′-substitutions were shown to have
no substrate activities for PARP1-catalyzed PARylation. In con-
trast, 2 and 4 with terminal alkyne groups modified at NR 3′-OH
display strong to moderate activities for PARP1 automodification,
respectively (Supplementary Figs. 31 and 32).
Next, kinetic parameters of NAD+, 2, and 6 for PARP1-
catalyzed automodification (PARP activity) and hydrolysis
(NADase activity) were determined by HPLC-based activity
assays (Table 1). The kcat of 6 for PARP1 auto-PARylation is
4.1 ± 0.6 min−1 (mean ± standard deviation of three replicates),
only slightly lower than that of NAD+ (4.7 ± 0.4 min−1). The Km
(370.5 ± 104.8 µM) of 6 is higher than that (145.4 ± 36 µM) of
NAD+. The kcat of 2 is significantly lower than those of NAD+
and 6. Same as NAD+, 2 and 6 could undergo slow hydrolysis
catalyzed by PARP1. Similar to their PARP activities, the NADase
activity for 6 is comparable to that of NAD+. These results are
consistent with immunoblot analyses and support 3′-azido
NAD+ as an excellent substrate for PARP1-catalyzed PARylation.
Biological activities of 2 and 6 in cellular context. To evaluate
their biological activities in the cellular context, 2 and 6 were
introduced into HeLa cells through transient permeabilization of
the cell membrane, which has no significant effect on cell
viability27,39,40 (Supplementary Fig. 33). Cells without transient
permeabilization were used as controls (Supplementary Figs. 34
and 35). Confocal microscopic analysis of cells treated with 6
clearly revealed the extent and location of cellular ADP-
ribosylation (Fig. 4a). Hydrogen peroxide (H2O2) can induce
oxidative DNA damage in the nucleus, leading to activated
PARP1 and PARP2 for DNA repair. Consistent with previous
results, treatment of cells with H2O2 resulted in significantly
increased ADP-ribosylation in the nucleus, which were sup-
pressed by veliparib. In addition, immunoblot analyses of the
lysates of HeLa cells showed marked protein labeling for cells
treated with 2 and 6 (Fig. 4b and Supplementary Fig. 36). Con-
sistent with the confocal imaging study, treatment with H2O2
caused significantly increased protein labeling, possibly due to the
activated PARP1 and PARP2. Additions of veliparib inhibited
protein labeling detected in the absence and presence of H2O2.
Compared with imaging and labeling signals derived from 2
(Supplementary Fig. 36), the analogue 6 exhibited improved
signal-over-background and sensitivity for both imaging and
protein labeling studies, consistent with its excellent substrate
activity for PARP1 as determined from immunoblot and enzyme
kinetic assays. Collectively, these results support 3′-azido NAD+
as a valuable tool for studying cellular PARylation.
Comparison of 6 and 2 with adenine-modified NAD+ analo-
gues. The substrate activity of 6 and 2 were then compared with
previously reported NAD+ analogues with modified adenines
(Fig. 5). For this purpose, 6-alkyne-NAD+ (6-a-NAD+) and
2-alkyne-NAD+ (2-a-NAD+) were synthesized according to
published methods (Fig. 5b)41,42, which show strong activities for
PARP124,27,41,42. Relative to 6, 6-a-NAD+ and 2-a-NAD+ exhibit
comparable Km, but significantly lower kcat for PARP1 auto-
PARylation (Table 1). The immunoblot analyses of their substrate
activities for PARP1-catalyzed auto-PARylation showed con-
sistent results that PARP1 modified by 6 displayed significantly
higher PARylation signals (Fig. 5c). In addition to PARP1, these
NAD+ analogues were examined for substrate activities for its
close relative PARP2 that catalyzes protein PARylation. Similar to
PARP1, human PARP2 auto-PARylated by 6 showed significantly
higher signals relative to 6-a-NAD+ and 2-a-NAD+ (Fig. 5d).
Furthermore, the substrate activities of 2, 6, 6-a-NAD+, and 2-a-
NAD+ for catalytic domains of human PARP5a and PARP10
were compared (Fig. 5e, f), which catalyze protein PARylation
and mono-ADP-ribosylation (MARylation), respectively. Unlike
6-a-NAD+ and 2-a-NAD+ that displayed strong automodifica-
tion activities for both enzymes, 2 and 6 revealed little activities
Table 1 Kinetic parameters of NAD+ and its analogues for
human PARP1
Substrate kcat (min-1)a Km (μM)a kcat/Km
(min−1 M-1)
PARP
activity
NAD+ 4.7 ± 0.4 145.4 ± 36.0 3.2 × 104
2 0.06 ± 0.01 218.1 ± 81.7 2.8 × 102
6 4.1 ± 0.6 370.5 ± 104.8 1.1 × 104
6-a-NAD+ 1.9 ± 0.5 603.1 ± 307.9 3.2 × 103
2-a-NAD+ 1.4 ± 0.4 400.8 ± 238.2 3.5 × 103
NADase
activity
NAD+ 0.39 ± 0.08 471.5 ± 187.4 8.3 × 102
2 0.02 ± 0.01 661.1 ± 489.0 0.3 × 102
6 0.46 ± 0.17 326.9 ± 278.8 1.4 × 103
6-a-NAD+ 0.36 ± 0.02 370.8 ± 47.5 9.7 × 102
2-a-NAD+ 0.47 ± 0.13 545.9 ± 313.5 8.6 × 102
aData are shown as mean ± standard deviation of three replicates
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Fig. 3 Substrate activities of NAD+ and 6 for human PARP1. Auto-
PARylation of PARP1 with 400 µM NAD+ or 6 was analyzed by
immunoblots using an anti-PAR antibody (a) and a streptavidin-HRP
conjugate following biotin conjugation via click chemistry (b). PARP1
loading controls were detected by an anti-His6 antibody. Source data are
provided as a Source Data file
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for auto-ADP-ribosylation catalyzed by PARP5a and PARP10
under the same conditions. These results reveal that 6 is a more
selective substrate with excellent activity for PARP1 and PARP2.
In addition to their substrate activities, the stability of the PAR
polymers formed by these NAD+ analogues were compared upon
treatment by human PARG, one of the major enzymes
responsible for degrading PAR polymers (Fig. 6). In contrast to
NAD+- and 6-a-NAD+-derived PAR polymers that were rapidly
removed by PARG, 2-a-NAD+- and 6-based PAR polymers show
comparable resistance to PARG-mediated degradation.
Next, 6 was applied to label protein PARylation in cell lysates
for comparion with those labeled by NAD+ and 2-a-NAD+,
which causes higher level of labelling than 6-a-NAD+ (Fig. 7a, b).
By using a WWE domain-based reagent48 that exhibits compar-
able binding toward PAR polymers formed by NAD+, 6, and 2-a-
NAD+ (Supplementary Fig. 37), immunoblot analyses indicated
that 6 results in more significant labelling of protein PARylation
in cell lysates relative to NAD+ and 2-a-NAD+ (Fig. 7c, d).
Analysis of mitochondrial protein PARylation by 6. To further
demonstrate its utility, 6 was applied to examine mitochondrial
protein PARylation. In addition to the nucleus as the pre-
dominant subcellular location for protein PARylation, multiple
studies indicated the presence of PARylation in mitochon-
dria49–54. In vitro biochemical assays also confirmed several
mitocohondrial proteins as PARP1 substrates24. Despite
emerging but debating roles of PARylation in regulating
mitochondrial DNA metabolism, limited approaches are
available for studying mitochondrial PARylation and activity-
based probes have yet to be developed for analyzing mito-
chondrial PARylation. Considering its high activity and speci-
ficity for protein PARylation, 6 was attempted to label
mitochondrial PARylation in cells permeabilized with 0.025%
Triton X-100. Confocoal microscopy indicated that in addition
to the predominant PARylation in nucleus, considerable
PARylation signals were colocalized with mitofilin, a
mitochondrial inner membrane protein (Fig. 8a), suggesting the
presence of PARylation in mitochondria. Consistent with
confocal imaging results, immunoblot analysis of the isolated
mitochondria fractions clearly revealed significant protein
labeling in the presence of 6. And treatment of cells with H2O2
resulted in increased protein labeling by 6 in the mitochondria
fractions, which were suppressed by veliparib inhibitor
(Fig. 8b). Moreover, a considerable amount of PARP1 was
detected in mitochondrial fractions (Fig. 8b), which is con-
sistent with previous studies52–54 and suggests its important
role in catalyzing protein PARylation in mitochondria. Taken
together, these results provide direct evidence for mitochon-
drial PARylation through an activity-based probe, demon-
strating 6 as a valuable tool for studying cellular PARylation.
Discussion
In summary, a 3′-azido NAD+ with unexpected high activity and
selectivity for protein PARylation was generated. By exploiting
recombinant human NRK1 and NMNAT1, this ribose-
functionalized NAD+ molecule could be enzymatically synthe-
sized in high efficiency and yields from its NR and NMN ana-
logue precursors, establishing a facile approach for the production
of 3′-azido NAD+. In contrast to established NAD+ analogues, 6
may represent a robust tool with enhanced activity and sensitivity
for studying cellular PARylation. The enhanced labelling by 6
likely results from faster kinetics for PARylation and increased
resistance to PAR removal by PARG.
The lack of substrate activity for 5 could be possibly caused by
the blocked formation of branched PAR, which requires access to
free 2′-OH of NR for covalently attaching ADP-ribose units, and/
or the significantly decreased cleavage rate of the N-glycosidic
bond resulting from adjacent electron-withdrawing 2′-azido
group55. Substitutions of NR 3′-OH for terminal alkyne and azido
groups result in NAD+ analogues recognized by PARP1 for
PARylation. The extended loop (G876-I895) at PARP1 active site
may accommodate 3′-OH modifications (Fig. 5a) and the
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increased size and/or flexibility of the functional groups could
cause decreased substrate activities for PARP1.
The high specificity and activity of 6 for PARP1 and PARP2
could be attributed to the extended loop (G876-I895) and (G442-
I461) at PARP1 and PARP2 active sites, respectively, which
possibly involve in the interactions with the NR 3′-OH mod-
ification and are nearly identical for PARP1 and PARP2, but
show large variations in length and sequence among PARP1/
PARP2, PARP5a, and PARP10 (Fig. 5a, g). It should be noted that
in addition to this extended loop, more subtle differences at the
catalytic sites of these PARP enzymes could result in different
activities with 6. In addition, further work is required to char-
acterize the PAR polymers formed by 6, including the individual
steps of initiation, elongation, and branching for PARP1-
catalyzed PARylation with 6 as the substrate.
Additionally, the substrate activity of 6 for recombinant human
sirtuin 2 (SIRT2), an NAD+-dependent protein deacetylase, was
examined by using a trypsin-coupled fluorescence-based activity
assay. It was found that in overnight reactions 6 displays no
substrate activity for human SIRT2, suggesting that 6 is not a
substrate of SIRT2 and azido substitution at 3′-OH of NR moiety
is not tolerated by SIRT2 (Supplementary Fig. 38).
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Automodifications of PARP1, PARP2, PARP5a and PARP10 with NAD+ analogues were carried out by incubating PARP enzymes with NAD+ analogues in
the absence and presence of 100 μM olaparib at 30°C for 2 h. The reaction mixtures were then labeled with azido-biotin (for NAD+, 2, 6-a-NAD+, and 2-a-
NAD+) or alkyne-biotin (for NAD+ and 6) through click chemistry, followed by immunoblot analysis as detected by the streptavidin-HRP conjugate.
PARP1, PARP2, PARP5a or PARP10 catalytic domain loading controls were detected by an anti-His6 antibody or anti-PARP2 antibody. Automodification of
PARP enzymes normalized to respective PARPs was analyzed by densitometry. ns: not significant, P > 0.05; **P < 0.01; and ***P < 0.001 by one-tailed
unpaired t-test. Error bars represent standard deviation of three replicates. g The loops at the catalytic sites of PARP1, PARP2, PARP5a and PARP10.
Loops were overlaid based on the solved X-ray structures of PARP1 (red; PDB ID: 6BHV)43, PARP2 (magenta, PDB ID: 4ZZX)44, PARP5a (yellow; PDB ID:
3UH4)45 and PARP10 (blue; PDB ID: 5LX6)46. Primary sequences were aligned for the loops at the catalytic sites of PARP1 (G876-I895), PARP2
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This work provides a valuable tool for studying NAD+-depen-
dent PARylation. Notably, the success in generation of this ribose-
functionalized NAD+ with robust biological activities potentially
enables further development of bi- and multi-functional NAD+
molecules as innovative research tools for investigating cellular
signaling and processes mediated by ADP-ribosylation.
Methods
General materials and methods. 1H NMR spectra were recorded on an Oxford
AM-400 spectrometer for solution in CDCl3, CD3OD or D2O. Coupling constants J
are shown in Hz. 13C NMR spectra were recorded on an Oxford AM-400 spec-
trophotometer (100MHz) with complete proton decoupling spectrophotometer
(CDCl3: 77.0 ppm). Flash column chromatography was performed using 230–400
mesh silica gel (Sigma–Aldrich, St. Louis, MO). For thin-layer chromatography
(TLC), silica gel plates (Sigma-Aldrich GF254) were used. HPLC was performed on
a Waters 2487 series with C18 Kinetex column (5 µm, 100 Å, 150 × 10.0 mm, from
Phenomenex Inc, Torrance, CA). cDNA of human NRK1 (accession number:
BC036804) and human NMNAT1 (accession number: BC014943) were purchased
from GE Dharmacon (Lafayette, CO). TAMRA-alkyne, azide-fluor 545 (N3-Fluor
545), DAPI, β-NAD+, azide-PEG3-biotin and alkyne-PEG4-biotin, and Calf thy-
mus DNA (activated) were purchased from Sigma–Aldrich. Streptavidin-HRP
conjugate was purchased from R&D Systems (Minneapolis, MN). Veliparib was
purchased from Selleckchem (Houston, TX). Dithiothreitol (DTT) was purchased
from VWR International (Radnor, PA). Trichloroacetic acid (TCA), Pierce Coo-
massie Plus (Bradford) assay kit, and goat anti-mouse IgG secondary antibody-
HRP conjugate (Thermo Fisher Scientific: G-21040) were purchased from Thermo
Fisher Scientific (Waltham, MA). Anti-poly-(ADP-ribose) antibody (10H) was
purchased from Santa Cruz (Dallas, TX). Recombinant human PARP2 with N-
terminal GST tag (product# SRP0193) was purchased from Sigma–Aldrich. HeLa
cells were obtained from the American Type Culture Collection (ATCC) (Mana-
ssas, VA) and tested negative for mycoplasma. All other reagents were purchased
from readily available commercial sources and used without further purification.
Synthesis and characterization of NAD+ analogues. The experimental details
and results for synthesis of the NAD+ analogues 1–6, 2-a-NAD+, and 6-a-NAD+
are provided in the Supplementary Information.
Cloning and generation of NRK1 and NMNAT1. Protein sequence of human
NRK1:MKTFIIGISGVTNSGKTTLAKNLQKHLPNCSVISQDDFFKPESEIET
DKNGFLQYDVLEALNMEKMMSAISCWMESARHSVVSTDQESAEEIPILIIEGF
LLFNYKPLDTIWNRSYFLTIPYEECKRRRSTRVYQPPDSPGYFDGHVWPMY
LKYRQEMQDITWEVVYLDGTKSEEDLFLQVYEDLIQELAKQKCLQVTAH
HHHHH.
Protein sequence of human NMNAT1:MENSEKTEVVLLACGSFNPITNMH
LRLFELAKDYMNGTGRYTVVKGIISPVGDAYKKKGLIPAYHRVIMAELATK
NSKWVEVDTWESLQKEWKETLKVLRHHQEKLEASDCDHQQNSPTLERPG
RKRKWTETQDSSQKKSLEPKTKAVPKVKLLCGADLLESFAVPNLWKSEDITQ
IVANYGLICVTRAGNDAQKFIYESDVLWKHRSNIHVVNEWIANDISSTKIRR
ALRRGQSIRYLVPDLVQEYIEKHNLYSSESEDRNAGVILAPLQRNTAEAKT
HHHHHH.
The open reading frames (ORFs) of human NRK1 (528 bp) and NMNAT1 (840
bp) with C-terminal His6-tags were amplified through polymerase chain reaction
(PCR) using primers of NRK1-Fw/Rv and NMNAT1-Fw/Rv, respectively
(Supplementary Table 1). NcoI and XhoI restriction enzyme sites were placed at 5
´- and 3´-end of the primers, respectively. After digestion with NcoI and XhoI
restriction enzymes, the amplified DNA fragments and backbone of pET-28a (+)
vector were purified using gel DNA recovery kits (Zymo Research, CA), followed
by ligation using the T4 DNA ligase. All constructed bacterial expression vectors
were verified by DNA sequencing (Genewiz LLC, NJ).
To express human NRK1 and NMNAT1, BL21 (DE3) cells were electroporated
with the expression constructs and grown in LB Broth containing 50 µg mL−1 of
kanamycin. After overnight growth, 5 mL of culture was transferred into 1 liter of
LB Broth containing 50 µg mL−1 of kanamycin and grown in an incubator shaker
(250 rpm; Series 25, New Brunswick Scientific, NJ) at 37 °C until the OD600 nm
reached 0.6–0.8. After addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) to induce protein expression, the bacterial culture was grown in an
incubator shaker (250 rpm) overnight at 18 °C, followed by centrifugation at
4550 × g (Beckman J6B Centrifuge, JS-4.2 rotor) and resuspension in lysis buffer
(20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 20 mM imidazole). Cells were then lysed
by passing three times through French Press (GlenMills, NJ) at 25,000 psi and
centrifuged at 4 °C for 1 h at 14,000 × g (Beckman Coulter centrifuge, JA-17 rotor)
to remove debris. The supernatants were filtered using 0.45 µm membranes and
loaded on gravity flow columns with 1 mL of Ni-NTA agarose resins (Thermo
Fisher Scientific, Waltham, MA). After washing the columns with 15 column
volumes of washing buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 30 mM
imidazole), the NRK1 and NMNAT1 were eluted using 15 column volumes of
elution buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 400 mM imidazole).
Fractions containing of eluted proteins were combined and dialyzed in the storage
buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1 mM DTT, 10% glycerol)
overnight at 4 °C. After another 6-h dialysis in fresh storage buffer, the purified
proteins were concentrated by Amicon centrifugal concentrators (10 kDa cutoff;
EMD Millipore, Temecula, CA) and analyzed by SDS-PAGE. Protein
concentrations were determined by NanoDrop 2000C spectrophotometer (Thermo
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Fisher Scientific, Waltham, MA) using calculated molecular extinction coefficient
(1.537 for NRK1-His6 and 1.592 for NMNAT1-His6). Aliquoted proteins were
flash-frozen in liquid nitrogen and stored at −80 °C.
HPLC of enzymatic conversion of NR and NMN analogues. NRK1 and
NMNAK1 were used to catalyze the conversion processes from NR analogues to
NMN analogues and from NMN analogues to NAD+ analogues, respectively. Both
enzymes were used in the conversion from NR analogues to NAD+ analogues. All
the conversion reactions were performed at room temperature in 100 µL assay
solutions containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 20 mM MgCl2,
1 mM DTT, 5 mM ATP, 1 mM NR/NMN analogues and 5 μM purified enzymes.
After the indicated incubation time, the reactions were stopped by adding 50%
TCA to a final concentration of 10%. After centrifugation at 12,000 × g for 5 min,
the supernatants of reaction mixtures were analyzed by reverse-phase HPLC using
a semipreparative C18 Kinetex column (5 µm, 100 Å, 150 × 10.0 mm, from Phe-
nomenex Inc, Torrance, CA) with a gradient of methanol (0–40% in 20 min) in
water containing 0.1% formic acid.
Purity analysis of NAD+ analogues 1–6. Each NAD+ analogue (500 μM) was
analyzed separately by reverse-phase HPLC using a semipreparative C18 Kinetex
column (5 µm, 100 Å, 150 × 10.0 mm, from Phenomenex Inc, Torrance, CA)
(mobile phase A: 0.1% formic acid (aq); mobile phase B: 0.1% formic acid in
methanol; flow rate= 2.0 ml min−1; 0–2 min: 0–4% B, 2–4 min: 4–10% B, 4–6 min:
10–20% B, 6–12 min: 20–50% B, 12–14 min: 50–0% B) with detection of UV
absorbance at 260 nm. The purity of 1–6 was calculated based on the proportion of
their corresponding integrated peak areas in the total integrated peak areas.
Cloning and generation of human PARP1. cDNA of human PARP1 (accession
number: BC037545) was purchased from GE Dharmacon (Lafayette, CO). Full-
length human PARP1 with a C-terminal His6-tag was amplified through PCR using
primers PX (5′-TGGTGCTCGAGCCACAGGGAGGTCTTAAAATTGAATTTCA
GT-3′) and PY (5′-CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA
TATACCATGGCGGAGTCTTCGGATAAGC-3′) purchased from Integrated
DNA Technologies (IDT) (Coralville, IA). The amplified full-length PARP1 and
pET-28a (+) vector were digested by XhoI and XbaI restriction enzymes, purified
using gel DNA recovery kits (Zymo Research, CA), and then ligated using the T4
DNA ligase. The resulting expression construct for full-length human PARP1 was
verified by DNA sequencing (Genewiz LLC, NJ).
The expression and purification of full-length human PARP1 were performed
on the basis of a previous report with minor modifications56. Briefly, BL21 (DE3)
cells were electroporated with the constructed pET-28a vector encoding full-length
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human PARP1 and grown in LB Broth media containing 50 µg mL−1 of kanamycin
for overnight. Each liter of LB Broth with 50 µg mL−1 of kanamycin was then
inoculated with 10 mL of overnight bacterial culture and grown at 37 °C in an
incubator shaker (250 rpm; Series 25, New Brunswick Scientific, NJ) until the
OD600 nm reached 0.6–0.8, followed by addition of ZnSO4 (final concentration:
0.1 mM). At an OD600 nm of 0.8–1.0, the flasks were removed and incubated on
ice for 1 h, followed by induction of protein expression with 0.5 mM IPTG for
overnight at 16 °C, centrifugation at 4550 × g (Beckman J6B Centrifuge, JS-4.2
rotor), and resuspension in lysis buffer (25 mM HEPES pH 8.0, 500 mM NaCl,
1 mM PMSF). Cells were lysed by passing a French Press (GlenMills, NJ) for three
times at 25,000 psi and then centrifuged at 27,000 × g for 100 min (Beckman
Coulter centrifuge, JA-17 rotor) at 4 °C. The collected supernatants were then
filtered by passing through 0.45 µm membranes, followed by loading on a gravity
flow column with 5 mL of Ni-NTA agarose resins (Thermo Fisher Scientific,
Waltham, MA), washing with 50 mL of low-salt wash buffer (25 mM HEPES pH
8.0, 500 mM NaCl, 20 mM imidazole), 50 mL of high-salt wash buffer (25 mM
HEPES pH 8.0, 1 M NaCl, 20 mM imidazole) and 50 mL of low-salt wash buffer.
Proteins were then eluted with 25 mL elution buffer (25 mM HEPES pH 8.0,
500 mM NaCl, 400 mM imidazole). Twenty-five milliliter no-salt buffer (50 mM
Tris pH 7.0, 1 mM EDTA, 0.1 mM DTT) was then added to the eluted proteins and
the proteins were loaded onto a 5-mL HiTrap Heparin HP Column by a low-
pressure peristaltic pump at a flow rate of at 3 mLmin−1 (GE Healthcare,
Princeton, NJ). Heparin column was placed on an ÄKTA Pure chromatography
system to elute PARP1 using a gradient of 0–100% buffer B (50 mM Tris pH 7.0,
1 mM EDTA, 0.1 mM DTT, 1M NaCl) in buffer A (50 mM Tris pH 7.0, 1 mM
EDTA, 0.1 mM DTT, and 250 mM NaCl) at a flow rate of 1 mLmin−1. PARP1 was
eluted starting at 40% buffer B and the collected fractions were combined and spun
down to 500 µL using Amicon centrifugal filters with 30 kDa cutoff (EMD
Millipore, Temecula, CA). The concentrated proteins were injected on to a size-
exclusion chromatography column Superdex 200 Increase 10/300 GL (GE
Healthcare, Princeton, NJ) and eluted using gel filtration buffer (25 mM HEPES,
pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1 mM DTT). Purified PARP1 was examined
by SDS-PAGE and a NanoDrop 2000C spectrophotometer (Thermo Fisher
Scientific, Waltham, MA), then aliquoted and flash-frozen in liquid nitrogen for
storage at −80 °C. Calculated molecular extinction coefficient value for human
PARP1 with a C-terminal His6-tag is 1.052.
Auto-PARylation of PARP1 with 1–6. Auto-PARylation of purified PARP1 was
performed at room temperature in 100 µL assay solutions containing 100 mM Tris-
HCl, pH 8.0, 50 mM NaCl, 20 mM MgCl2, 1 mM DTT, 100 ng uL−1 activated
DNA, 0.4 mM NAD+ or NAD+ analogues 1–6, and 1 μM purified PARP1 enzyme.
PARP1 automodification controls were performed with 100 μM veliparib inhibitor.
After indicated incubation time, the reactions were stopped by adding 100 μM
veliparib.
The reaction mixtures were further labeled with azide-biotin (for 1–4) or
alkyne-biotin (for 5 and 6) through copper(I)-catalyzed azide alkyne cycloaddition
(CuAAC). Click reactions were performed for 2 h at room temperature in 45 μL
volume, which contain 30 μL PARP1 automodification mixtures, 2 mM THPTA,
1 mM CuSO4, 100 μM azide/alkyne-biotin, and 10 mM sodium ascorbate in PBS.
The levels of auto-PARylation were evaluated by immunoblot using an anti-
PAR monoclonal antibody (clone: 10H, from Santa Cruz Biotechnology sc-56198;
1:500 dilution) for detection of the formation of ADP-ribose polymer, a
streptavidin-HRP conjugate (R&D Systems: DY998; 1:200 dilution) for detection of
the biotinylated PARP1 via click chemistry, and an anti-His6 antibody (clone: HIS.
H8, from Thermo Fisher Scientific MA1-21315; 1:2000 dilution) for detection of
PARP1 as loading control. The goat anti-mouse IgG antibody-HRP conjugate
(Thermo Fisher Scientific: G-21040; 1:3000 dilution) was used as the secondary
antibody for the anti-PAR antibody and anti-His6 antibody. Uncropped and
unprocessed scans of the blots are provided as a Source Data file.
HPLC-based kinetic assays. Auto-PARylation of PARP1 was carried out in 80 µL
assay solutions (30 mM HEPES, pH 8.0, 5 mM MgCl2, 5 mM CaCl2, 1 mM DTT,
100 ng µL−1 of activated DNA, 100 ng µL−1 BSA) containing varied concentrations
of NAD+ (50, 100, 250, 450, 600 and 750 µM) or NAD+ analogues (2, 6, 6-a-
NAD+, and 2-a-NAD+) at 30 °C with purified PARP1 enzymes. The reactions
were quenched at different time points (NAD+: 0, 2.5, 5, 10, 15, and 20 min; 2:
0, 60, 120, 180, 240 and 300 min; 6: 0, 5, 10, 15, 20 and 30 min; 6-a-NAD+ and
2-a-NAD+: 0, 10, 20, 30, and 40 min) using 20% ice-cold TCA. After centrifuga-
tion, the reaction mixtures were analyzed by reverse-phase HPLC using a semi-
preparative C18 Kinetex column (5 µm, 100 Å, 150 × 10.0 mm, from Phenomenex
Inc, Torrance, CA) (mobile phase A: 0.1% formic acid (aq); mobile phase B: 0.1%
formic acid in acetonitrile; flow rate= 2.0 mLmin−1; 0–8 min: 0% B, 8–12 min:
0–50% B, 12–13 min: 50–2.5% B, 13–18 min: 2.5–40% B, 18–20 min: 40–0% B)
with detection of UV absorbance at 260 nm. The retention times for NAD+, 2, 6,
6-a-NAD+ and 2-a-NAD+ were 13.0, 13.6, 13.6, 14.0 and 13.8 min, while for
ADPr, ADPr2, ADPr6, ADPr6-a-NAD+, and ADPr2-a-NAD+, the retention times
were 6.3, 12.9, 9.0, 13.0, and 14.2 min. Standard curves for NAD+ and NAD+
analogues together with ADPr and ADPr analogues were constructed by linear
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correlations of concentrations and corresponding integrated peak areas. NADase
reaction rates were determined based on the increase in peak areas of the assigned
peaks of ADPr and ADPr analogues, while reaction rates for PARP activities were
measured based on the decrease in peak areas of the assigned peaks of NAD+ and
NAD+ analogues excluding NADase activity. Kinetic parameters were determined
by fitting data to the Michaelis-Menten model implemented in GraphPad Prism
(La Jolla, CA).
Cellular PARylation assays. Detection of PARylation activities in oxidatively
stressed cells was performed by following a previously established assay with minor
modifications27. HeLa cells were first incubated with 500 μM H2O2 in PBS for
20 min. As negative controls, cells were pre-incubated for 2 h with 1 μM veliparib
prior to the additions of H2O2, followed by washing once with PBS. For pre-
permeabilized groups, cells were incubated with reaction buffer (56 mM HEPES,
28 mM KCl, 28 mM NaCl, 2 mM MgCl2, pH 8.0) complemented with 0.01% Tri-
ton-X-100, and 100 μM NAD+ analogues for 15 min at 4 °C. After removal of the
reaction buffer with 0.01% Triton-X-100, cells were washed with PBS and incu-
bated with reaction buffer and 100 μM/200 μM NAD+ analogues in the absence of
Triton-X-100 for 45 min at 37 °C, followed by washing three times with PBS. For
non-permeabilized control groups, cells were incubated with reaction buffer (56
mM HEPES, 28 mM KCl, 28 mM NaCl, 2 mM MgCl2, pH 8.0) and 100 μM/200 μM
NAD+ analogues for 1 h at 37 °C, followed by washing three times with PBS. For
control experiments, veliparib was added in all experimental steps.
For confocal imaging analysis, cells were fixed with 4% para-formaldeyhde
(PFA) for 20 min at room temperature, followed by washing three times with PBS,
permeabilization with 0.5% Triton-X-100 in PBS for 20 min at room temperature,
and washing twice with 3% BSA/PBS. CuAAC reactions were performed with
10 mM THPTA, 5 mM CuSO4, 5 μM alkyne-TAMRA or azide-Fluor 545, 50 mM
sodium ascorbate in PBS at room temperature for one hour, followed by washing
three times with PBS. Cell nuclei were stained with DAPI (1 μg mL−1 in PBS) for
20 min at room temperature, followed by washing three times with PBS and
confocal microscopic analysis using a Leica SP8 confocal laser scanning microscope
(Leica Microsystems Inc., Buffalo Grove, IL) equipped with a 63×, 1.4 NA PLAPO
oil immersion objective lens. DAPI, TAMRA, and Fluor-545 were excited at
405 nm, 557 nm, and 545 nm, respectively. Images were processed using LAS X
software (Leica Microsystems Inc., Buffalo Grove, IL).
For immunoblot analysis, cells were harvested and lysed on ice for 15 min using
M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific,
Waltham, MA) with protease inhibitors. After centrifugation at 12,000 × g for
10 min at 4 °C, proteins in supernatant were labeled with biotin for 2 h at room
temperature by performing CuAAC reactions in 45 μL click solution, which
contained 30 μL cell lysates, 2 mM THPTA, 1 mM CuSO4, 100 μM azide/alkyne-
biotin, and 10 mM sodium ascorbate in PBS buffer. The reaction mixtures were
analyzed by immunoblot using a streptavidin-HRP conjugate (R&D Systems:
DY998; 1:200 dilution) for biotinylated cellular proteins and an anti-GAPDH
antibody (clone: GA1R, from Thermo Fisher Scientific MA5–15738; 1:3000
dilution) for detecting the levels of GAPDH as loading controls. The goat anti-
mouse IgG antibody-HRP conjugate (Thermo Fisher Scientific: G-21040; 1:3000
dilution) was used as the secondary antibody for the anti-GAPDH antibody.
Uncropped and unprocessed scans of the blots are provided as a Source Data file.
The effect of transient permeabilization on cell viability was evaluated with
trypan blue and (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(MTT), respectively. HeLa cells were incubated with reaction buffer (56 mM
HEPES, 28 mM KCl, 28 mM NaCl, 2 mM MgCl2, pH 8.0) complemented with
0.01% Triton-X-100 for 15 min at 4 °C. After removal of the reaction buffer with
0.01% Triton-X-100, cells were washed with PBS and incubated with fresh medium
at 37 °C. HeLa cells incubated with reaction buffer or medium in the same
condition were included as controls. Following 1-h incubation, cell viability was
determined by the trypan blue method. The numbers of blue staining cells and the
numbers of total cells were examined by optical microscopy. The percentage of
viable cells was calculated as: %viable cells= [1.00− (number of blue cells/number
of total cells)] × 100. Following 24-h incubation, cell viability was determined by
MTT assays. The cells were incubated with MTT solution for 2 h to allow viable
cells to reduce the yellow tetrazolium salt (MTT) into dark blue formazan crystals.
100 μL of lysis buffer (20% SDS in 50% dimethylformamide, pH 4.7) was then
added to wells and incubated for 2 h at 37 °C. The absorbance was measured at
570 nm using a BioTek Synergy H1 Hybrid Multi-Mode Microplate reader. Percent
viability was calculated as: %cell viability= [(absorbanceexperimental−
absorbancespontaneous average)/(absorbancemaximum viability average−
absorbancespontaneous average)] × 100.
To detect PARylation activities in mitochondria, HeLa cells were treated as
described above except that 0.025% Triton-X-100 was used in the permeabilization
process.
For confocal imaging analysis, cells were blocked with 3% BSA/PBS for 30 min
at room temperature after the CuAAC reactions as described above, and then
incubated with Alexa Fluor 488 conjugated anti-mitofilin antibody (1:200 in 3%
BSA/PBS; clone: MM#7A-2E4AD5, from Thermo Fisher Scientific MA4-56400-
A488) for 1 h at room temperature, followed by washing three times with PBS. Cell
nuclei were stained with DAPI (1 μg mL−1 in PBS) for 20 min at room
temperature, followed by washing three times with PBS and confocal microscopic
analysis using a Leica SP8 confocal laser scanning microscope (Leica Microsystems
Inc., Buffalo Grove, IL) equipped with a 63×, 1.4 NA PLAPO oil immersion
objective lens. DAPI, TAMRA, and Fluor-488 were excited at 405 nm, 557 nm, and
488 nm, respectively. Images were processed using LAS X software (Leica
Microsystems Inc., Buffalo Grove, IL).
For immunoblot analysis, cells were harvested, and mitochondria fractions were
isolated using Qproteome Mitochondria Isolation Kit (from QIAGEN, Cat No.:
37612) by following the manufacturer’s protocol. Isolated mitochondria fractions
were lysed on ice for 15 min using lysis buffer (25 mM Tris-HCl pH 7.5, 50 mM
NaCl, 10% glycerol, 1% Nonidet P-40) with protease inhibitors. After
centrifugation at 12,000 × g for 10 min at 4 °C, proteins in supernatants were
labeled with biotin for 2 h at room temperature by performing CuAAC reactions as
described above. The reaction mixtures were analyzed by immunoblots using a
streptavidin-HRP conjugate (R&D Systems: DY998; 1:200 dilution) for biotinylated
proteins, a monoclonal anti-COX IV antibody (clone: 3E11, from Cell Signaling
Technology #4844; 1:3000 dilution) for COX IV as mitochondrial protein loading
controls, a monoclonal anti-GAPDH antibody (clone: GA1R, from Thermo Fisher
Scientific MA5-15738; 1:3000 dilution) for GAPDH as a cytoplasmic protein
marker, a polyclonal anti-Histone 2A.Z antibody (from Cell Signaling Technology
product #2718S; 1:500 dilution) for Histone 2A.Z as a nuclear protein marker, and
a monoclonal anti-PARP1 antibody (clone: 46D11, from Cell Signaling Technology
#2718S; 1:2000 dilution) for PARP1. The goat anti-mouse IgG antibody-HRP
conjugate (Thermo Fisher Scientific: G-21040; 1:3000 dilution) was used as the
secondary antibody for the anti-GAPDH antibody and the goat anti-rabbit IgG
antibody-HRP conjugate (Thermo Fisher Scientific: G-21234; 1:3000 dilution) was
used as the secondary antibody for the anti-COX IV antibody, anti-Histone 2A.Z
antibody and anti-PARP1 antibody. Uncropped and unprocessed scans of the blots
are provided as a Source Data file.
Generation of human PARP5a and PARP10 catalytic domains. cDNAs of
human PARP10 (accession number: BC144235) and PARP5a (GE Dharmacon:
MHS6278-202806376) were used as templates for polymerase chain reaction to
amplify the catalytic domains (residues 809-1017 and residues 1093-1327 for
PARP10 and PARP5a, respectively) and add a His6-tag at the N-terminus or
C-terminus. Primers #1 (5′- GCCGGATCTCAGTGGTGGTGGTGGTGGTGC
TCGAGTTATTACCCAGAGGGGTCGTCGGG-3′) and #2 (5′- AAGGAGATAT
ACCATGCACCATCATCATCATCATATTGAGGGTCGCGCGGGGCAGACGC
TGAAGG-3′) were used to amplify PARP10, and primers #3 (5′- GTGGTGCTC
GAGTTATTAATGATGATGATGATGGTGGGTCTTCTGCTCTGCGGCTGTT
G-3′) and #4 (5′-TTAACTTTAAGAAGGAGATATACCATGACCAATCCTTAT
TTGACTTTTCACTGTGTTAATCAG-3′) were used to amplify PARP5a. PCR
products were verified by agarose gel electrophoresis and an additional round of
PCRs were completed using primers #5 (5′- TTCCCCTCTAGAAATAATTT
TGTTTAACTTTAAGAAGGAGATATACCATGCACCATCATCATC-3′) and #1
to extend the PCR product of PARP10 and primers #6 (5′- TTCCCCTCTAGA
AATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGACCAATCCT-3′)
and #3 for PARP5a. The PCR products were purified by agarose gel electrophoresis
and digested using XbaI and XhoI (New England Biolabs) for 1 h at 37 °C. pET-28a
(+) plasmids were digested overnight using XbaI and XhoI at 37 °C and cut vector
was purified from agarose gel electrophoresis. Digested PCR fragments and vector
were ligated using T4 DNA Ligase (New England Biolabs) for 1 h at room tem-
perature prior to transformation into DH10B electrocompetent cells.
Sequence-verified plasmids were then transformed into BL21 (DE3) cells for
bacterial expression and purification. 5 mL of LB broth with 50 µg mL−1
kanamycin were inoculated with transformed BL21 (DE3) cells with the plasmids
encoding PARP10 and PARP5a catalytic domains and grown overnight at 37 °C at
250 rpm. Each overnight culture was inoculated into 1 L of LB broth with
50 µg mL−1 kanamycin and grown to OD600 nm= 0.8 at 37 °C at 250 rpm. Protein
expression was induced using a final concentration of 500 µM IPTG and grown
overnight at 22 °C at 250 rpm. Cells were harvested by centrifuging for 30 min at
2,700 × g and discarding the supernatant. Cell pellets were resuspended in 30 mL
equilibrium buffer (20 mM Tris pH 7.5, 500 mM NaCl, 20 mM imidazole) with
1 mgmL−1 lysozyme (Amresco Inc.), 10 µg mL−1 DNase I (Roche), 0.1 mM MgCl2
and 0.1 mM phenylmethylsulfonyl fluoride (Chem-Impex Int’l. Inc.). Cells were
lysed by running cells through a French press (Glen Mills Inc.) at 25,000 psi three
times. Cell debris was spun down at 27,000 × g. 1 mL of Ni-NTA agarose resin
(Thermo Fisher Scientific) was loaded onto a gravity flow column and washed with
15 column volume (CV) of water and 15 CV of equilibrium buffer before running
cell lysate through. The column was then washed with 15 CV of equilibrium buffer
and 15 CV of wash buffer (20 mM Tris pH 7.5, 500 mM NaCl, 30 mM imidazole).
Bound proteins were eluted with 15 CV elution buffer (20 mM Tris pH 7.5,
500 mM NaCl, 400 mM imidazole). Proteins were concentrated with 10 kDa
MWCO ultra-15 centrifugal filter units (Amicon) before running through an
AKTA FPLC (GE Healthcare) with a SuperDex 75 10/300 column (GE Healthcare)
preequilibrated with storage buffer (20 mM Tris pH 7.5, 300 mM NaCl, 10%
glycerol, 1 mM DTT). An isocratic gradient with a flow rate of 0.5 mLmin−1 was
used to separate 0.5 mL fractions, which were run on a PAGE gel to identify
fractions containing the desired proteins. Fractions were combined and
concentrated by the centrifugal filter units. Protein concentrations were examined
by SDS-PAGE and spectrophotometry, analyzing the wavelength at 280 nm and
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using extinction coefficients of 0.762 and 0.753 for PARP10 and PARP5a,
respectively.
Substrate activities of NAD+ analogues for PARPs. Auto-PARylation of pur-
ified PARP1 was performed at room temperature in 100 µL of assay solutions
containing 100 mM Tris-HCl, pH 8.0, 50 mM NaCl, 20 mM MgCl2, 0.2 mM DTT,
100 ng μL−1 activated DNA, 0.4 mM NAD+ or NAD+ analogues 2, 6, 6-a-NAD+,
2-a-NAD+, and 1 μM purified PARP1 enzyme. PARP1 automodification controls
were performed with 100 μM olaparib inhibitor. After indicated incubation time,
the reactions were stopped by adding 100 μM olaparib.
Auto-PARylation of recombinant human PARP2 was performed at room
temperature in 10 µL of assay solutions containing 100 mM Tris-HCl, pH 8.0,
50 mM NaCl, 20 mM MgCl2, 0.2 mM DTT, 100 ng μL−1 activated DNA, 0.1 mM
NAD+ or NAD+ analogues 2, 6, 6-a-NAD+, 2-a-NAD+, and 200 ng purified
PARP2 enzyme. PARP2 automodification controls were performed with 100 μM
olaparib inhibitor. After indicated incubation time, the reactions were stopped by
adding 100 μM olaparib.
Auto-PARylation of the purified PARP5a catalytic domain was performed at
room temperature in 100 µL of assay solutions containing 100 mM Tris-HCl, pH
8.0, 200 mM NaCl, 20 mM MgCl2, 0.2 mM DTT, 0.4 mM NAD+ or NAD+
analogues 2, 6, 6-a-NAD+, 2-a-NAD+, and 10 μM purified PARP5a catalytic
domain. PARP5a automodification controls were performed with 100 μM olaparib
inhibitor. After indicated incubation time, the reactions were stopped by adding
100 μM olaparib.
Auto-MARylation of the purified PARP10 catalytic domain was performed at
room temperature in 100 µL of assay solutions containing 100 mM Tris-HCl, pH
8.0, 200 mM NaCl, 20 mM MgCl2, 0.2 mM DTT, 0.4 mM NAD+ or NAD+
analogues 2, 6, 6-a-NAD+, 2-a-NAD+, and 20 μM purified PARP10 catalytic
domain. PARP10 automodification controls were performed with 100 μM olaparib
inhibitor. After indicated incubation time, the reactions were stopped by adding
100 μM olaparib.
The reaction mixtures were further labeled with azide-biotin (for NAD+, 2, 6-a-
NAD+, and 2-a-NAD+) or alkyne-biotin (for NAD+ and 6) through copper(I)-
catalyzed azide alkyne cycloaddition (CuAAC). Click reactions were performed for
2 h at room temperature in 45 μL volume, which contained 30 μL of PARP1/2/5a/
10 automodification mixtures, 2 mM THPTA, 1 mM CuSO4, 100 μM azide/alkyne-
biotin, and 10 mM sodium ascorbate in PBS.
The levels of automodification were evaluated by immunoblot using a
streptavidin-HRP conjugate (R&D Systems: DY998; 1:200 dilution) for detection of
the biotinylated PARP1/2/5a/10 via click chemistry, an anti-His6 antibody (clone:
HIS.H8, from Thermo Fisher Scientific MA1-21315: 1:2000 dilution) for detection
of PARP1/5a/10 as loading controls, and an anti-PARP2 antibody (clone: F-3, from
Santa Cruz Biotechnology sc-393310; 1:200 dilution) for detection of PARP2 as
loading controls. The goat anti-mouse IgG antibody-HRP conjugate (Thermo
Fisher Scientific: G-21040; 1:3000 dilution) was used as the secondary antibody for
the anti-His6 antibody and anti-PARP2 antibody. Uncropped and unprocessed
scans of the blots are provided as a Source Data file.
PARG-mediated degradation of ADP-ribose polymers. Auto-PARylation of
PARP1 was performed at 30 °C overnight using 3 µM purified PARP1 and 400 µM
NAD+ or NAD+ analogues in a reaction buffer containing 100 mM Tris-HCl pH
8.0, 10 mM MgCl2 50 mM NaCl, 1 mM DTT, and 100 ng μL−1 activated DNA. 10
ng of human PARG (Sigma–Aldrich: SRP8023) was added to 300 ng of PARP1
auto-modified with NAD+ or NAD+ analogues in PBS in a total volume of 10 µL
for 30 min at room temperature to degrade ADP-ribose polymers. Two hundred
nanogram of the reaction was quenched with LDS loading dye (Thermo Fisher
Scientific: NP0008) and 100 ng was used for CuAAC before being quenched with
LDS loading dye. One hundred nanogram of each quenched reaction was run on
precast PAGE gels for detection by an anti-His6 antibody, Fc-WWE antibody
(EMD Millipore: MABE1031), or streptavidin-HRP conjugate. Proteins were
transferred onto PVDF membrane and blocking was done with 5% nonfat milk in
PBS with 0.05% Tween-20 (PBST) for 1 h at room temperature for detection by the
Fc-WWE antibody and anti-His6 antibody. 3% BSA in PBST was used for blocking
the membrane for 1 h at room temperature for detection by the streptavidin-HRP
conjugate. The Fc-WWE antibody was used at 1:5000 in PBST, anti-His6 antibody
was used at 1:3000 in PBST, and streptavidin-HRP conjugate was used at 1:200 in
PBS for 1 h at room temperature. Anti-rabbit antibody-HRP conjugate (secondary
antibody of System Biosciences: ExoAb-CD63A-1; 1:3000 dilution) was used as the
secondary antibody for the Fc-WWE antibody and anti-mouse antibody-HRP
conjugate (Thermo Fisher Scientific: G-21040; 1:3000 dilution) was used as the
secondary antibody for the anti-His6 antibody for 1 h. Detection was done using
SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scien-
tific: 34580). Images were analyzed and quantified using ImageJ (https://imagej.nih.
gov/ij/index.html)57.
Binding of WWE domain to auto-modified PARP1. Auto-PARylation of PARP1
was performed at 30 °C overnight using 3 µM purified PARP1 and 400 µM NAD+
or NAD+ analogues 6 and 2-a-NAD+ in a reaction buffer containing 100 mM
Tris-HCl pH 8.0, 10 mM MgCl2 50 mM NaCl, 1 mM DTT, and 100 ng μL−1
activated DNA. Ten nanogram of PARP1 auto-modified with NAD+ and NAD+
analogues 6 and 2-a-NAD+ were diluted into 100 µL of PBS and plated into 96-well
high-binding plates (Greiner Bio-One: 655077) and incubated overnight at room
temperature. Following three washes using 400 µL of PBST, wells were blocked
with 300 µL 3% BSA in PBS for 2 h at room temperature. This was followed by
another three washes with PBST before adding the Fc-WWE antibody at 1:5000 in
PBST supplemented with 0.1% BSA for 2 h at room temperature. An anti-rabbit
antibody-HRP conjugate was used as the secondary antibody at a dilution factor of
1:3000 in PBST with 0.1% BSA for 1 h at room temperature. Detection was done
using QuantBlu Fluorogenic Peroxidase Detection (Thermo Fisher Scientific:
15169) with an excitation wavelength of 325 nm and an absorption wavelength of
420 nm. Results and graphs were generated using Graphpad Prism (GraphPad
Software, La Jolla, CA).
Preparation of HeLa cell lysates. HeLa cells were grown in T25 flasks to 90%
confluency and then collected using trypsin to detach the cells from the flasks
before spinning down and washing the cell pellet with PBS. Two hundred
microliter of lysis buffer (25 mM Tris-HCl pH 7.5, 50 mM NaCl, 10% glycerol, 1%
Nonidet P-40 (VWR: 97064-734), and Halt Protease Inhibitor Cocktail (Thermo
Fisher Scientific: 78430)) was used to resuspend the cell pellets. Cells were shaken
for 10 min at room temperature before spinning down cellular debris at 14,000 × g
at 4 °C for 15 min. Protein concentrations of the cell lysates were measured using
Bradford reagent (Thermo Fisher Scientific: 23236).
Labeling of protein PARylation in cell lysates. Two hundred micromolar of
NAD+ or NAD+ analogue was added to 10 µg of lysate diluted in PBS to a final
volume of 10 μL. Reactions were incubated at 30 °C for 1 h. Five microgram of
lysate was quenched by the addition of LDS loading dye and analyzed on PAGE
gels; the remaining 5 µg was subjected to CuAAC before quenching with LDS dye
and run on PAGE gels. Proteins were transferred onto PVDF membranes and
blocked with 5% nonfat milk or 3% BSA. Protein PARylation was detected using
the streptavidin-HRP conjugate for 2-a-NAD+ and 6-a-NAD+ or Fc-WWE anti-
body for 6 and 2-a-NAD+. The anti-rabbit antibody-HRP conjugate was used as
the secondary antibody for the Fc-WWE antibody. The anti-GAPDH antibody was
used for a loading control at 1:3000 in PBST, and the anti-mouse antibody-HRP
conjugate was used at 1:3000 as the secondary antibody. Detection was done as
described above. Images were analyzed by ImageJ.
Substrate activities of NAD+ and 6 for human SIRT2. 0.5mM NAD+ or 6 was
incubated with 0.25 mM acetylated peptide substrate Ac-Arg-Gly-Lys(Ac)-AMC
(R&D System, MN) and 45.4 nM recombinant human SIRT2 (R&D System, MN) in
buffer containing 25mM Tris pH 8.0, 150mM NaCl, 1 mM DTT for overnight at
room temperature. Reactions without SIRT2 were included as controls. Following the
overnight reactions, 50 nM bovine trypsin (Sigma-Aldrich, MO) was added to reac-
tion mixtures for cleaving the deacetylated peptide substrate and releasing fluorescent
7-amino-4-methylcoumarin (AMC) group (excitation 380 nm; emission 460 nm).
The reactions were monitored by using Synergy H1 microplate reader (Biotek, VT) on
the basis of fluorescence intensity.
Statistical analysis. One-tailed unpaired t tests were performed for comparison
between two groups. A P < 0.05 was considered statistically significant. Significance
of finding was defined as: ns= not significant, P > 0.05; *P < 0.05; **P < 0.01; and
***P < 0.001. Data are shown as mean ± SD. All statistical analyses were calculated
using GraphPad Prism (GraphPad Software, CA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors confirm that the data supporting the findings of this study are available from
the corresponding author upon request. The source data underlying Figs. 3, 4b, 5c–f, 6, 7
and 8b and Supplementary Figs. 22, 31–33, 34b–36b, 37, and 38 are provided as a Source
Data file.
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